Keith Lenden

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

ARCH Venture Partners LLC is a Venture Capital firm founded in 1986. The firm is headquartered in Chicago with additional office in Dublin.

Acologix, Inc. develops and commercializes medicines. The company was founded by Yoshinari Kumagai in 1992 and is headquartered in Hayward, CA.

Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA.

Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.

The Henry J. Kaiser Family Foundation, do-business-as Kaiser Family Foundation (KFF), is a non-profit, private operating foundation headquartered in San Francisco, California. The firm was founded in 1948, but it was completely remade in 1991. The foundation focuses on national health issues and the US role in global health policy. KFF develops and runs their own policy analysis, journalism and communications programs, sometimes in partnership with major news organizations.

Genteric, Inc. develops revolutionary therapeutic protein delivery technology. It is a biotech company formed to commercialize several proprietary technology platforms that harness the body's own protein production and distribution system. Genteric proprietary technology captures natural protein manufacturing capability for therapeutic benefit. The company is headquartered in Redwood City, CA.